Fragment Based Drug Discovery Market

Fragment Based Drug Discovery Market (Component: Fragment Screening and Fragment Optimization; End-user: Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Fragment Based Drug Discovery Market Outlook 2031

  • The global industry was valued at US$ 795.4 Mn in 2022
  • It is projected to advance at a CAGR of 11.5% from 2023 to 2031 and reach US$ 2.1 Bn by the end of 2031

Analysts’ Viewpoint

The global fragment-based drug discovery (FBDD) market is expected to grow at a rapid pace during the forecast period. FBDD has emerged as a promising approach in early-stage drug development. Higher hit rates, increased chemical diversity, and ability to target challenging proteins are likely to propel market expansion in the near future. Furthermore, increase in incidence of complex diseases, such as cancer and neurological disorders, is likely to fuel global fragment based drug discovery market demand in the next few years.

Development of biophysical techniques, such as NMR spectroscopy, X-ray crystallography, and SPR, offers lucrative opportunities to market players. Companies are increasing investment in R&D, collaborative efforts, and technological innovations to increase market presence. However, challenges related to optimization process, high cost, and regulatory requirements are projected to hamper global fragment based drug discovery market value in the near future.

Fragment Based Drug Discovery Market

Global Fragment Based Drug Discovery Market Introduction

Fragment-based drug discovery (FBDD) is an innovative approach used in early-stage drug development. Instead of traditional high-throughput screening (HTS) of large and complex molecules, FBDD involves screening small, low molecular weight fragments as starting points. These fragments interact with target proteins, providing valuable information for lead optimization.

FBDD offers several advantages, including increased chemical diversity, higher hit rates, and the ability to target challenging proteins that are difficult to address through conventional methods.

Biophysical techniques, such as NMR spectroscopy, X-ray crystallography, and SPR, are commonly used to screen and optimize fragments efficiently. This method has gained prominence in the pharmaceutical industry due to its potential to accelerate drug discovery and development, leading to the creation of novel and more effective therapeutic agents for various diseases and medical conditions.

Higher Hit Rates & Enhanced Chemical Diversity Fueling Fragment Based Drug Discovery Industry

Fragment-based drug discovery (FBDD) has emerged as a powerful and efficient approach in early-stage drug development, offering higher hit rates and enhanced chemical diversity compared to traditional high-throughput screening (HTS) methods. This has garnered significant attention from the pharmaceutical industry and research institutions seeking innovative solutions for drug discovery.

FBDD's ability to achieve higher hit rates stems from its unique screening strategy. It focuses on testing small, low molecular weight fragments. These fragments, often consisting of simple chemical structures, have a higher likelihood of interacting with target proteins. Consequently, FBDD leads to the identification of more hits or starting points for further drug development, streamlining the process of lead discovery.

In June 2023, AbbVie announced promising findings on the sustained long-term safety and efficacy of VENCLYXTO/ VENCLEXTA (venetoclax)-based combination therapies for CLL patients using fragment-based drug discovery. FBDD facilitated the identification of venetoclax, a successful drug targeting BCL-2, discovered through fragment screening and optimization. The study showcased improved PFS, higher rates of uMRD, and enhanced disease control in previously untreated CLL patients with co-existing conditions. These results underscore FBDD's significance in identifying lead compounds for transformative fixed-duration therapies, demonstrating lasting benefits and treatment opportunities for patients with CLL.

FBDD's ability to target challenging proteins and protein-protein interactions further contributes to its higher hit rates and enhanced chemical diversity. Conventional HTS methods often struggle to identify compounds that interact with complex and hard-to-reach target sites.

In contrast, FBDD's small fragments can penetrate such challenging regions and provide valuable information for lead optimization. This has been particularly valuable in addressing previously undruggable targets, expanding the potential for developing drugs for diseases that were previously difficult to tackle.

Expanded Application in Therapeutic Areas Driving Fragment Based Drug Discovery Market Growth

Fragment-based drug discovery (FBDD) has emerged as a versatile and promising approach in the pharmaceutical industry due to its applicability across various therapeutic areas. One of the key advantages of FBDD lies in its ability to explore and identify small, low-molecular-weight fragments. These fragments can be optimized to develop potent and selective drug candidates, making FBDD a valuable tool in the quest for novel therapeutics.

In the field of oncology, FBDD has shown significant potential in targeting specific cancer-associated proteins. For instance, researchers at a leading biotech company used FBDD to identify small molecule fragments that bind to an oncogenic protein involved in promoting tumor growth.

In May 2023, Evotec AG launched its Innovation Centre for Fragment-Based Drug Discovery (FBDD) in Hamburg, Germany, and Oxford, the U.K. The center aims to identify novel, small molecule hits (fragments) for challenging biological targets using its EVOlution platform. The platform combines ultra-sensitive screening technologies and protein-ligand X-ray crystallography to detect low molecular weight fragments in a biologically relevant environment. Evotec has validated the technology against various therapeutic targets, including CNS, oncology, inflammation, metabolic disease, and cardiovascular diseases.

High Efficiency in Terms of Speed & Cost Driving Demand for Fragment Screening

In terms of component type, the fragment screening segment accounted for the largest global fragment based drug discovery market share in 2022. The segment includes services such as library screening, biophysical screening (NMR, X-ray crystallography), and computational screening.

Fragment screening enables the exploration of a vast chemical space using small, low molecular weight compounds. These fragments can access unique binding sites on target proteins that larger molecules might not be able to reach, potentially leading to the discovery of novel binding modes and unprecedented drug leads.

Fragment screening provides valuable information about the binding interactions between fragments and target proteins. By using biophysical techniques, such as NMR and X-ray crystallography, researchers can gain insights into the atomic-level interactions, guiding the subsequent optimization process effectively.

Fragment screening is highly efficient in terms of speed and cost. Screening smaller libraries of fragments is faster and more cost-effective than traditional high-throughput screening of larger compound libraries. This allows for a more streamlined and focused drug discovery process.

Rise in Demand for High Specificity & Sensitivity in Cancer Research & Drug Development

Based on application, the oncology segment is likely to dominate the global industry during the forecast period. This is ascribed to significant focus on cancer research and drug development.

Major pharmaceutical companies have increased investment in oncology-focused FBDD research and have initiated multiple collaborations with specialized FBDD providers. These partnerships aim to identify novel drug candidates for various oncology targets, including those that have been historically challenging to drug using conventional methods.

Astex Pharmaceuticals, renowned for its success in the oncology field, is now leveraging its fragment-based drug discovery (FBDD) platform to target neurodegenerative diseases in the central nervous system (CNS). The company aims to apply its expertise in FBDD to identify small molecule fragments that interact with specific proteins involved in neurodegenerative processes.

By utilizing this approach, Astex seeks to develop novel and targeted therapies for diseases such as Alzheimer's and Parkinson's. With a track record of success in oncology, Astex's expansion into the CNS field holds significant promise for advancing drug discovery efforts and addressing the urgent medical needs of patients suffering from neurodegenerative conditions.

Focus on Discovering Innovative Therapeutics Bolstering Demand for FBDD

In terms of end-user, the pharmaceutical & biotechnology companies segment is anticipated to account for largest global fragment based drug discovery market size during the forecast period. These companies are projected to drive adoption of FBDD services due to their substantial research & development budgets and strong focus on discovering innovative therapeutics.

Drug discovery is facing challenges with few clinical candidates reaching commercialization. Pharmaceutical/biotech R&D spending - around US$ 182 Bn in 2019 - has risen due to increasing complexity. Over 16,000 drug molecules were evaluated, emphasizing the resource-intensiveness. The industry strives to mitigate risks and meet growing patient demand for innovative therapies.

The segment's dominance can be attributed to rise in demand for novel drug candidates and the need to expedite the drug discovery process. Furthermore, as pharmaceutical and biotech firms increasingly seek external expertise and partnerships to complement their in-house capabilities, FBDD service providers become integral in delivering effective and targeted drug candidates. Hence, the segment is anticipated to witness the fastest growth during the forecast period.

Regional Outlook

As per fragment based drug discovery market trends, North America dominated the global industry in 2022. The trend is expected to continue during the forecast period. This can be ascribed to substantial investment by key players in FBDD research & development, well-established infrastructure, and robust healthcare systems in the U.S. and Canada. North America is often at the forefront of adopting technological advancements, making it a base for implementing FBDD techniques.

Demand for FBDD is increase in Asia Pacific, fueled by surge in investment in healthcare infrastructure and strong emphasis on improving quality management, particularly in countries such as China and Japan. Hence, the region is emerging as a potential market for FBDD services.

Analysis of Key Players

Increase in investment in R&D and collaboration are the key strategies adopted by leading players in order to increase global fragment based drug discovery market revenue and share.

Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Charles River Laboratories International, Inc., Beactica AB, Emerald BioStructures, Inc., Crown Bioscience, Inc., Evotec AG, Proteros Fragments GmbH, Kinetic Discovery Limited, Sprint Bioscience, Sygnature Discovery and Structure Based Design, Inc. are the prominent players in the market.

Key Developments in Global Fragment Based Drug Discovery Market

  • In February 2023, Astex Pharmaceuticals and Cardiff University Medicines Discovery Institute joined forces in a multi-year, multimillion pound drug discovery collaboration. The aim is to identify new drugs for the treatment of neurodegenerative diseases. The collaboration will leverage Astex's fragment-based drug discovery platform and the research expertise of Dr. Emyr Lloyd-Evans and Dr. Helen Waller-Evans in lysosomal biology to advance potential therapeutic options for these challenging conditions.
  • In April 2019, Charles River Laboratories International, Inc. and CHDI Foundation announced extension of their collaboration to focus on high-content and fragment-based screening to identify potential drug candidates for Huntington's disease (HD). High-content screening evaluates numerous compounds by analyzing multiple cellular parameters, enabling the identification of compounds that target HD-relevant processes.

Prominent players have been profiled in the fragment based drug discovery market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Fragment Based Drug Discovery Market Snapshot

Attribute Detail

Size in 2022

US$ 795.4 Mn

Forecast (Value) in 2031

More than US$ 2.1 Bn

Growth Rate (CAGR)

11.5%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Component
    • Fragment Screening
      • Biophysical Techniques
        • NMR Spectroscopy
        • Differential Scanning Fluorimetry (DSF) Assay
        • Fluorescence Polarization
        • Isothermal Titration Calorimetry
        • X-ray Crystallography
        • Surface Plasmon Resonance (SPR)
        • Bilayer Interferometry
        • Mass Spectrometry (MS)
        • Capillary Electrophoresis
        • Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • Other assays (biochemical)
      • Non-biophysical Techniques
    • Fragment Optimization
  • Application
    • Oncology
    • Central Nervous System (CNS) Disorders
    • Infectious Diseases
    • Cardiovascular Diseases
    • Metabolic Disorders
    • Inflammation & Autoimmune Diseases
  • End-user
    • Academic & Research Institutions
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs)

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Alveus Pharmaceuticals Pvt. Ltd.
  • Astex Pharmaceuticals
  • Charles River Laboratories International, Inc.
  • Beactica AB
  • Emerald BioStructures, Inc.
  • Crown Bioscience, Inc.
  • Evotec AG
  • Proteros Fragments GmbH
  • Kinetic Discovery Limited
  • Sprint Bioscience
  • Sygnature Discovery
  • Structure Based Design, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global fragment based drug discovery market in 2022?

It was valued at US$ 795.4 Mn in 2022.

How big will be the fragment based drug discovery business by 2031?

It is projected to reach more than US$ 2.1 Bn by 2031.

What will be the CAGR of the fragment based drug discovery industry during the forecast period?

It is anticipated to advance at a CAGR of 11.5% from 2023 to 2031.

Which are the major factors driving demand for fragment based drug discovery?

Higher hit rates & enhanced chemical diversity, expanded application in various therapeutic areas, and increase in interest in drug discovery research.

What was the share of the leading fragment based drug discovery segment?

The fragment screening component segment accounted for more than 57.0% share in 2022.

Which region will account for major share of the fragment based drug discovery sector during the forecast period?

North America is expected to account for the largest share from 2023 to 2031.

Who are the prominent fragment based drug discovery players?

Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Charles River Laboratories International, Inc., Beactica AB, Emerald BioStructures, Inc., Crown Bioscience, Inc., Evotec AG, Proteros Fragments GmbH, Kinetic Discovery Limited, Sprint Bioscience, Sygnature Discovery and Structure Based Design, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Fragment Based Drug Discovery Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Fragment Based Drug Discovery Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Key Industry Events

        5.3. Regulatory Scenario by Region/Globally

        5.4. Major Research Institutes Involved

        5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Component

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Component, 2017-2031

            6.3.1. Fragment Screening

                6.3.1.1. Biophysical Techniques

                    6.3.1.1.1. NMR Spectroscopy

                    6.3.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    6.3.1.1.3. Fluorescence Polarization

                    6.3.1.1.4. Isothermal Titration Calorimetry

                    6.3.1.1.5. X-ray Crystallography

                    6.3.1.1.6. Surface Plasmon Resonance (SPR)

                    6.3.1.1.7. Bilayer Interferometry

                    6.3.1.1.8. Mass Spectrometry (MS)

                    6.3.1.1.9. Capillary Electrophoresis

                    6.3.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    6.3.1.1.11. Other Assays (Biochemical)

                6.3.1.2. Non-biophysical Techniques

            6.3.2. Fragment Optimization

        6.4. Market Attractiveness Analysis, by Component

    7. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Application, 2017-2031

            7.3.1. Oncology

            7.3.2. Central Nervous System (CNS) Disorders

            7.3.3. Infectious Diseases

            7.3.4. Cardiovascular Diseases

            7.3.5. Metabolic Disorders

            7.3.6. Inflammation & Autoimmune Diseases

        7.4. Market Attractiveness Analysis, by Application

    8. Global Fragment Based Drug Discovery Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017-2031

            8.3.1. Academic & Research Institutions

            8.3.2. Pharmaceutical & Biotechnology Companies

            8.3.3. Contract Research Organizations (CROs)

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Global Fragment Based Drug Discovery Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Component, 2017-2031

            10.2.1. Fragment Screening

                10.2.1.1. Biophysical Techniques

                    10.2.1.1.1. NMR Spectroscopy

                    10.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    10.2.1.1.3. Fluorescence Polarization

                    10.2.1.1.4. Isothermal Titration Calorimetry

                    10.2.1.1.5. X-ray Crystallography

                    10.2.1.1.6. Surface Plasmon Resonance (SPR)

                    10.2.1.1.7. Bilayer Interferometry

                    10.2.1.1.8. Mass Spectrometry (MS)

                    10.2.1.1.9. Capillary Electrophoresis

                    10.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    10.2.1.1.11. Other Assays (Biochemical)

                10.2.1.2. Non-biophysical Techniques

            10.2.2. Fragment Optimization

        10.3. Market Value Forecast, by Application, 2017-2031

            10.3.1. Oncology

            10.3.2. Central Nervous System (CNS) Disorders

            10.3.3. Infectious Diseases

            10.3.4. Cardiovascular Diseases

            10.3.5. Metabolic Disorders

            10.3.6. Inflammation & Autoimmune Diseases

        10.4. Market Value Forecast, by End-user, 2017-2031

            10.4.1. Academic & Research Institutions

            10.4.2. Pharmaceutical & Biotechnology Companies

            10.4.3. Contract Research Organizations (CROs)

        10.5. Market Value Forecast, by Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Component

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Global Fragment Based Drug Discovery Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Component, 2017-2031

            11.2.1. Fragment Screening

                11.2.1.1. Biophysical Techniques

                    11.2.1.1.1. NMR Spectroscopy

                    11.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    11.2.1.1.3. Fluorescence Polarization

                    11.2.1.1.4. Isothermal Titration Calorimetry

                    11.2.1.1.5. X-ray Crystallography

                    11.2.1.1.6. Surface Plasmon Resonance (SPR)

                    11.2.1.1.7. Bilayer Interferometry

                    11.2.1.1.8. Mass Spectrometry (MS)

                    11.2.1.1.9. Capillary Electrophoresis

                    11.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    11.2.1.1.11. Other Assays (Biochemical)

                11.2.1.2. Non-biophysical Techniques

            11.2.2. Fragment Optimization

        11.3. Market Value Forecast, by Application, 2017-2031

            11.3.1. Oncology

            11.3.2. Central Nervous System (CNS) Disorders

            11.3.3. Infectious Diseases

            11.3.4. Cardiovascular Diseases

            11.3.5. Metabolic Disorders

            11.3.6. Inflammation & Autoimmune Diseases

        11.4. Market Value Forecast, by End-user, 2017-2031

            11.4.1. Academic & Research Institutions

            11.4.2. Pharmaceutical & Biotechnology Companies

            11.4.3. Contract Research Organizations (CROs)

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Component

            11.6.2. By Application

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Global Fragment Based Drug Discovery Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Component, 2017-2031

            12.2.1. Fragment Screening

                12.2.1.1. Biophysical Techniques

                    12.2.1.1.1. NMR Spectroscopy

                    12.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    12.2.1.1.3. Fluorescence Polarization

                    12.2.1.1.4. Isothermal Titration Calorimetry

                    12.2.1.1.5. X-ray Crystallography

                    12.2.1.1.6. Surface Plasmon Resonance (SPR)

                    12.2.1.1.7. Bilayer Interferometry

                    12.2.1.1.8. Mass Spectrometry (MS)

                    12.2.1.1.9. Capillary Electrophoresis

                    12.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    12.2.1.1.11. Other Assays (Biochemical)

                12.2.1.2. Non-biophysical Techniques

            12.2.2. Fragment Optimization

        12.3. Market Value Forecast, by Application, 2017-2031

            12.3.1. Oncology

            12.3.2. Central Nervous System (CNS) Disorders

            12.3.3. Infectious Diseases

            12.3.4. Cardiovascular Diseases

            12.3.5. Metabolic Disorders

            12.3.6. Inflammation & Autoimmune Diseases

        12.4. Market Value Forecast, by End-user, 2017-2031

            12.4.1. Academic & Research Institutions

            12.4.2. Pharmaceutical & Biotechnology Companies

            12.4.3. Contract Research Organizations (CROs)

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Component

            12.6.2. By Application

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Global Fragment Based Drug Discovery Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Component, 2017-2031

            13.2.1. Fragment Screening

                13.2.1.1. Biophysical Techniques

                    13.2.1.1.1. NMR Spectroscopy

                    13.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    13.2.1.1.3. Fluorescence Polarization

                    13.2.1.1.4. Isothermal Titration Calorimetry

                    13.2.1.1.5. X-ray Crystallography

                    13.2.1.1.6. Surface Plasmon Resonance (SPR)

                    13.2.1.1.7. Bilayer Interferometry

                    13.2.1.1.8. Mass Spectrometry (MS)

                    13.2.1.1.9. Capillary Electrophoresis

                    13.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    13.2.1.1.11. Other Assays (Biochemical)

                13.2.1.2. Non-biophysical Techniques

            13.2.2. Fragment Optimization

        13.3. Market Value Forecast, by Application, 2017-2031

            13.3.1. Oncology

            13.3.2. Central Nervous System (CNS) Disorders

            13.3.3. Infectious Diseases

            13.3.4. Cardiovascular Diseases

            13.3.5. Metabolic Disorders

            13.3.6. Inflammation & Autoimmune Diseases

        13.4. Market Value Forecast, by End-user, 2017-2031

            13.4.1. Academic & Research Institutions

            13.4.2. Pharmaceutical & Biotechnology Companies

            13.4.3. Contract Research Organizations (CROs)

        13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Component

            13.6.2. By Application

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Global Fragment Based Drug Discovery Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Component, 2017-2031

            14.2.1. Fragment Screening

                14.2.1.1. Biophysical Techniques

                    14.2.1.1.1. NMR Spectroscopy

                    14.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay

                    14.2.1.1.3. Fluorescence Polarization

                    14.2.1.1.4. Isothermal Titration Calorimetry

                    14.2.1.1.5. X-ray Crystallography

                    14.2.1.1.6. Surface Plasmon Resonance (SPR)

                    14.2.1.1.7. Bilayer Interferometry

                    14.2.1.1.8. Mass Spectrometry (MS)

                    14.2.1.1.9. Capillary Electrophoresis

                    14.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)

                    14.2.1.1.11. Other Assays (Biochemical)

                14.2.1.2. Non-biophysical Techniques

            14.2.2. Fragment Optimization

        14.3. Market Value Forecast, by Application, 2017-2031

            14.3.1. Oncology

            14.3.2. Central Nervous System (CNS) Disorders

            14.3.3. Infectious Diseases

            14.3.4. Cardiovascular Diseases

            14.3.5. Metabolic Disorders

            14.3.6. Inflammation & Autoimmune Diseases

        14.4. Market Value Forecast, by End-user, 2017-2031

            14.4.1. Academic & Research Institutions

            14.4.2. Pharmaceutical & Biotechnology Companies

            14.4.3. Contract Research Organizations (CROs)

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Component

            14.6.2. By Application

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Alveus Pharmaceuticals Pvt. Ltd.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Astex Pharmaceuticals

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Charles River Laboratories International, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Beactica AB

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Emerald BioStructures, Inc.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Crown Bioscience, Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Evotec AG

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Proteros Fragments GmbH

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Kinetic Discovery Limited

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. Sprint Bioscience

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

            15.3.11. Sygnature Discovery

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

            15.3.12. Structure Based Design, Inc.

                15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.12.2. Product Portfolio

                15.3.12.3. Financial Overview

                15.3.12.4. SWOT Analysis

                15.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 03: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    Table 04: Global Fragment Based Drug Discovery Market Size (US$ Million) Forecast, by Region, 2017-2031

    Table 05: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country, 2017-2031

    Table 06: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 07: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 08: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    Table 09: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 11: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 12 Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    Table 13: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 15: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 16: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    Table 17: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 19: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 20: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    Table 21: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031

    Table 23: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031

    Table 24: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01. Global Fragment Based Drug Discovery Market Size (US$ Million) and Distribution, by Region, 2022 and 2031

    Figure 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, 2017-2031

    Figure 03: Global Fragment Based Drug Discovery Market Value Share, by Component (2022)

    Figure 04: Global Fragment Based Drug Discovery Market Value Share, by Application (2022)

    Figure 05: Global Fragment Based Drug Discovery Market Value Share, by End-user (2022)

    Figure 06: Global Fragment Based Drug Discovery Market Value Share, by Component, 2022 and 2031

    Figure 07: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Screening, 2017-2031

    Figure 08: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Optimization, 2017-2031

    Figure 09: Global Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 10: Global Fragment Based Drug Discovery Market Value Share, by Application, 2022 and 2031

    Figure 11: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Oncology, 2017-2031

    Figure 12: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Central Nervous System (CNS) Disorders, 2017-2031

    Figure 13: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Infectious Diseases, 2017-2031

    Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Cardiovascular Diseases, 2017-2031

    Figure 14: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Metabolic Disorders, 2017-2031

    Figure 15: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Inflammation & Autoimmune Diseases, 2017-2031

    Figure 16: Global Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 17: Global Fragment Based Drug Discovery Market Value Share, by End-user, 2022 and 2031

    Figure 18: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Academic & Research Institutions, 2017-2031

    Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Pharmaceutical & Biotechnology Companies, 2017-2031

    Figure 20: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Contract Research Organizations (CROs), 2017-2031

    Figure 21: Global Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

    Figure 22: Global Fragment Based Drug Discovery Market Value Share, by Region, 2022 and 2031

    Figure 23: Global Fragment Based Drug Discovery Market Attractiveness, by Region, 2017-2031

    Figure 24: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%) 2017-2031

    Figure 25: North America Fragment Based Drug Discovery Market Value Share, by Country, 2022 and 2031

    Figure 26: North America Fragment Based Drug Discovery Market Attractiveness, by Country, 2017-2031

    Figure 27: North America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 28: North America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 29: North America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

    Figure 30: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 31: Europe Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031

    Figure 32: Europe Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 33: Europe Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 34: Europe Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 35: Europe Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

    Figure 36: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 37: Asia Pacific Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031

    Figure 38: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 39: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 40: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 41: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

    Figure 42: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 43: Latin America Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031

    Figure 44: Latin America Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 45: Latin America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 46: Latin America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 47: Latin America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

    Figure 48: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031

    Figure 49: Middle East & Africa Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031

    Figure 50: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 51: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031

    Figure 52: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031

    Figure 53: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031

Copyright © Transparency Market Research, Inc. All Rights reserved